Axovant gene therapies ltd. (AXGT)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent

-14,100

-13,800

-28,100

-9,046

-34,296

-33,835

-51,888

-25,319

-57,902

-69,086

-69,266

-52,833

-47,811

-42,252

-38,055

-29,671

-63,355

-15,166

-24,953

-10,285

-10,762

Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

10,000

Loss on disposal of fixed assets

8

0

-25

-138

-1

-9

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign currency translation adjustment

293

-552

972

-247

-92

113

-559

666

-664

-99

349

-378

0

0

0

-

-

-

-

-

-

Amortization of operating lease right-of-use assets

408

426

369

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation expense

2,312

891

2,135

3,555

4,558

2,457

5,859

-9,701

10,639

15,340

15,600

8,541

8,331

7,937

11,561

8,428

39,056

5,725

19,177

8,296

0

Depreciation and non-cash amortization

441

308

426

327

476

613

1,034

970

1,063

715

335

214

13

11

11

6

-6

13

1

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-896

-1,174

-306

976

788

-3,353

5,274

79

-2,492

-3,040

1,170

2,223

129

805

-1,565

1,046

1,787

2,002

25

2

2

Deferred tax assets

-

-

-

-

-

-

-

0

0

0

-2,709

2,386

283

-283

0

-

-

206

182

-

-

Income tax receivable

-83

155

190

146

50

-86

-135

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

0

-1

-340

-2,476

-875

540

3,784

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Accounts payable

-1,220

-1,329

1,198

680

-799

386

-2,518

2,917

-1,828

-5,687

-4

-700

-259

6,667

2,221

-2,934

2,859

66

228

117

0

Due to Roivant Sciences Ltd. and certain of its wholly owned subsidiaries

-

-21

-103

-

-

668

1,193

-312

-2,882

-224

1,547

-2,028

2,241

488

404

470

-1,115

678

-344

729

758

Accrued expenses

-1,093

-6,319

7,161

-2,292

-1,404

-818

-6,729

-3,073

1,141

-4,247

3,245

9,399

8,970

4,555

3,553

2,922

3,460

698

1,311

462

6

Operating lease liabilities

-

-

-369

-

-

-

0

-

23

-1,589

-566

-32

-263

121

174

87

-186

32

252

0

0

Net cash used in operating activities

-13,086

-18,746

-17,731

-

-33,477

-27,734

-61,413

-

-46,590

-61,639

-47,919

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,995

-18,566

-23,216

-15,434

-10,162

-4,535

-683

0

Cash flows from investing activities:
Purchase of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,000

Purchases of property and equipment

76

96

78

128

56

18

0

38

603

1,472

2,171

0

69

8

28

35

22

30

7

9

0

Net cash used in investing activities

-76

-96

-78

-

-56

-18

0

-

-603

-1,472

-2,171

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-8

-28

-531

-4,778

-30

-7

-9

-5,000

Cash flows from financing activities:
Payments on long-term debt

19,308

5,208

5,047

4,927

4,780

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

336,893

0

0

Initial public offering costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

667

1,684

25

0

Capital contribution received from Roivant Sciences, Inc.

27

48

28

801

671

422

0

-

-

-

-

-

-

-

-

1

-1

1

750

0

5,000

Repayment of amounts due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

627

0

0

Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

0

0

279

717

0

Payment of contingent liability

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,000

0

0

0

0

-

-

Cash proceeds from stock option exercises

0

81

5

42

175

108

10

0

71

739

747

26

0

10

0

-

-

-

-

-

-

Cash proceeds from issuance of common shares, net of costs

-

-

-

-

-

-

-

0

0

-113

134,628

0

0

0

0

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-19,281

-5,079

-5,014

-

27,746

25,544

10

-

71

626

135,375

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

10

-5,000

0

-1

-666

335,611

692

5,000

Net change in cash and cash equivalents

-

-23,921

-22,823

-

-

-2,208

-61,403

-

-47,122

-62,485

85,285

12,168

-29,259

-22,993

-23,594

-23,747

-20,213

-10,858

331,069

0

0

Unpaid initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-667

707

-

-

Non-cash operating activities:
Operating lease right-of-use assets recognized upon the adoption of ASC 842, Leases, on April 1, 2019

-

-

2,986

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities recognized upon and since the adoption of ASC 842, Leases, on April 1, 2019

117

0

2,400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amounts reclassified from other non-current assets to operating lease right-of-use assets upon the adoption of ASC 842, Leases, on April 1, 2019

0

0

586

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

475

601

198

5

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-